Propofol toxicity in the developing mouse heart mitochondria

Matthew B Barajas1, Sarah D Brunner2, Aili Wang1

  • 1Department of Anesthesiology, Columbia University Medical Center, New York, NY, USA.

Pediatric Research
|February 17, 2022
PubMed

Insights

Propofol infusion syndrome (PRIS) impairs heart mitochondria in newborns by disrupting energy production. This study reveals propofol causes mitochondrial dysfunction, explaining why children are vulnerable to PRIS.

Area of Science:

  • Biochemistry
  • Cardiology
  • Pediatrics

Background:

  • Propofol infusion syndrome (PRIS) is a life-threatening condition linked to prolonged propofol use.
  • Cardiac complications are common in pediatric PRIS and contribute to mortality.
  • The mechanisms of propofol toxicity in developing hearts remain unclear.

Purpose of the Study:

  • To investigate the specific effects of propofol on immature cardiac mitochondria.
  • To determine if propofol induces mitochondrial defects in newborn cardiomyocytes.

Main Methods:

  • Isolated cardiac mitochondria from newborn mice were exposed to propofol or intralipid in vitro.
  • Mitochondrial respiration, membrane potential (ΔΨ), and respiratory chain complex kinetics were assessed.
  • The effects of a coenzyme Q analog (CoQ0) were evaluated.

Main Results:

  • Propofol induced a dose-dependent increase in proton leak and impaired substrate oxidation at coenzyme Q (CoQ).
  • These mitochondrial defects prevented adequate ΔΨ generation in propofol-exposed cardiomyocytes.
  • Coenzyme Q0 addition reversed propofol-induced leak and enhanced Complex II+III activity.

Conclusions:

  • Propofol uncouples immature cardiomyocyte mitochondria via CoQ-sensitive proton leak.
  • Propofol interferes with electron transport at the CoQ level, impairing mitochondrial function.
  • These findings elucidate propofol toxicity mechanisms in the developing heart, explaining pediatric vulnerability to PRIS.
Abstract

Related Concept Videos